Flow cytometry
A test that rapidly measures cell-surface markers across many cells.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Purpose of the test
- Assessing markers such as CD19 and CD20 on lymphoma cells.
- Helps classify blood cell malignancies.
Informs decisions
- Classification of lymphoma subtypes.
- Compatibility of antibody therapy and cellular therapy.
How the test is done
Cells from a tissue or blood sample are passed one by one through a device that reads the markers.
- Sample type
- A suspension of cells from tissue, blood, or bone marrow
- Estimated result time
- Generally several working days.
Limitations
- Requires a living cell sample for optimal results.
- Results are read along with tissue pathology.
Not displayed
TanyaKanker does not display test-cost estimates. Ask the laboratory or facility providing the test for cost details directly.
Sources
- NCI Dictionary of Cancer Terms(lembaga)
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
To check
- Leukemia
Cancer type
Reason: Memerlukan pemeriksaan
- Lymphoma
Cancer type
Reason: Memerlukan pemeriksaan
- CAR-T (chimeric antigen receptor T-cell therapy)
Treatment category
Reason: Memerlukan pemeriksaan
- BCMA
Biomarker
Reason: Diperiksa melalui
- CD19
Biomarker
Reason: Diperiksa melalui
- CD20
Biomarker
Reason: Diperiksa melalui
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.